By Stephen Nakrosis
Starton Therapeutics said it was terminating its business combination deal with blank-check company Healthwell Acquisition Corp. I.
The deal, under which shares of the combined company were expected to begin trading on the Nasdaq, was announced in April.
Last month, Healthwell postponed a planned meeting for shareholders to vote on the proposed business combination.
The special purpose acquisition company filed for a $250 million initial public offering in February 2021.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
Read the full article here